Mitomics Granted Key Patents in the U.S., Europe, Singapore and New Zealand
Patents Protect Biomarker Used in Company’s Prostate Core Mitomic Test™
Thunder Bay, Ontario, Canada – October 19, 2011 – Mitomics, world leader in the research and development of mitochondrial genome-based products, announced today it has received notice from multiple international offices of the issuance of patents protecting key aspects of Mitomics’ flagship product, the Prostate Core Mitomic Test™ (PCMT™). The patents, issued in the U.S., Europe, Singapore and New Zealand, not only cover the specific mitochondrial biomarker used in PCMT, but also its application for the detection of prostate cancer. These jurisdictions are the first in a series in which Mitomics is expecting patents to grant.
Robert Poulter, president and chief executive officer, Mitomics commented, “The issuance of these patents aligns well with the regions where we currently market or are in negotiations to market PCMT. This validation significantly strengthens our proprietary position in the prostate cancer detection space, where feedback from urologists has been particularly strong. In fact, urologists have indicated that with its sensitivity of 84% and negative predictive value of 91%, PCMT is becoming their test of choice for all negative biopsy patients.”
Prostate cancer is the most commonly diagnosed cancer in males and the second leading cause of cancer death in the U.S. Every year, more than 230,000 American men are diagnosed with prostate cancer, and more than 30,000 die from the disease. If detected early, prostate cancer is often treatable. It is estimated that well over 1 million prostate biopsies are performed annually in the U.S., and although approximately 70 percent of all initial prostate biopsies are negative, it has been found that anywhere from 25 to 60 percent of these are positive on second or subsequent biopsy.
Mitomics’ PCMT harnesses the powerful science of mitochondrial DNA and accurately determines the absence or presence of cancerous cells using previously obtained prostate biopsy tissue. It utilizes a unique cancerization field effect to identify molecular changes and enable detection of missed tumors.
About the Prostate Core Mitomic Test™
A prostate cancer biopsy is neither an easy nor painless procedure and can result in multiple complications. It only samples a small fraction of the prostate gland, potentially missing the tumor and contributing to a high false negative rate – even in second biopsies. With the highly sensitive Prostate Core Mitomic Test, you can know more by getting far more accurate and reliable results from biopsy tissue. The Prostate Core Mitomic Test is a highly advanced, proprietary test based on the science of mitochondrial DNA (mtDNA). Using previously obtained prostate biopsy tissue, the Prostate Core Mitomic Test can determine the presence of malignant cells via a cancerization field effect by detecting underlying molecular alterations in normal appearing tissue. This is all performed quickly and easily with a simple lab test. For more information or to order the Prostate Core Mitomic Test, please visit the PCMT web page.
Mitomics is the world leader in the research and development of mitochondrial DNA (mtDNA)-based biomarkers – a new and innovative approach to the detection of cancer and other disease states. Leveraging its unparalleled insights into the role of mitochondria in cancer, the company is developing an extensive and proprietary portfolio of molecular tests that address significant unmet needs in oncology and gynecology, including those for the early detection of prostate and breast cancer, as well as a test for endometriosis. Mitomics currently markets the Prostate Core Mitomic Test™, a highly accurate laboratory developed test for detecting the absence or presence of cancerous cells using existing prostate biopsy tissue, and plans to launch several additional breakthrough molecular tests based on its Mitomic Technology™ in the coming years. The company is headquartered in Thunder Bay, Ontario, Canada. For more information, please visit www.mitomicsinc.com.